Acuson co-founder and longtime chairman and CEO Samuel Maslak, DSc, has invested $1.5 million in tumor ablation therapy developer Thermedical and become chairman of its board of directors.
The Series A funding will be used for continued research and development and additional patent filings, as well as to help Thermedical obtain U.S. Food and Drug Administration (FDA) 510(k) clearance, according to the firm.
Thermedical said it is currently developing preclinical prototypes for a saline-enhanced radiofrequency ablation system (SERF) for treating malignant solid tissue, such as liver cancer, and for difficult-to-treat cardiac arrhythmias such as ventricular tachycardia.
